The representatives of Akron in the state of Ohio in the USA, who will arrive at the "2008 Biomed Israel Week" next month, are presenting a multi-million dollar plan for life science companies. Project value: 1.6 billion dollars. Among the benefits: up to a million dollars for each company, research funding, assistance in raising capital from international funds, and the purchase of space and equipment
According to Akron Mayor Donald Floskovlik, who will head the delegation for Biomed Week, "The state of Ohio has turned the recruitment of biotechnology and medical companies into a national project and has established a biomedical center in Akron, Ohio, designed to provide academic medical resources and local finance. In 2007 alone, the state of Ohio awarded 200 million dollars to companies that met the criteria."
Fluskvalik and Bob Bowman, the deputy mayor, will come to "Biomed Israel Week 2008" which will be held at the end of May in Tel Aviv, in order to present the project and offer Israeli Biomed companies to benefit from the support and financial support. They also offer collaborations between the researchers coming from Israel and the researchers located at the universities in Ohio. "The state of Ohio expresses continuous and frequent interest in the start-up companies as well as in the mature Israeli companies, and the incentives vary according to the size of the company, its stages, and the number of local employees planned to be employed by it," says Plovsovklik.
"ILSI - Biomed Israel 2008" week is the main event of the life sciences industry. It will be held this year (this is the seventh time) between May 27 and 29 at David Intercontinental and Dan Panorama in Tel Aviv. At the same time, two other events will be held: the 2nd International Conference on Stem Cell Research, and the ISRACAS 2008 Conference, the 11th Conference on Computer-Based Surgery, Medical Robotics and Medical Imaging. The Israeli Biomed Week is documented to attract, again this year, approximately 6,000 CEOs and executives of Biomed companies, scientists and researchers, managers of venture capital funds and angel investors, from Israel and abroad.
:
